Connect with us

INDUSTRIAL HEMP

AbbVie Inc. (NYSE:ABBV) Reports Positive Top-Line Data From IMMhance

Published

on

AbbVie Inc. (NYSE:ABBV) reported positive top-line data from IMMhance, which marks as the fourth pivotal Phase III clinical study assessing risankizumab for the cure of subjects with moderate-to-severe plaque psoriasis.

The details

AbbVie reported that there were two phases in IMMhance study. Data from the first phase demonstrated that following 16-weeks of treatment, risankizumab achieved the co-primary endpoints of minimum a 90% improvement in the PASI 90 and a sPGA score of clear or almost clear versus placebo. In the next phase of this trial, the main objective of sPGA 0/1 at one year was also achieved.

The second phase is evaluating the safety and efficacy of continuous therapy with risankizumab as compared to randomized withdrawal. Later, retreatment is also being assessed in this ongoing trial. Risankizumab is not permitted by regulatory authorities and its efficacy and safety have not been established. Data from IMMhance through week sixteen were showcased during an oral presentation on December 2.

Michael Severino, M.D., the EVP, R&D and CSO at AbbVie, reported that the positive report is consistent with the previous report that they have noted with risankizumab throughout the key Phase III clinical study program. With a notable portion of risankizumab subjects meeting high levels of skin clearance, the report supports the data supporting risankizumab’s prospect to be an effective new treatment alternative for people living with psoriasis. They look forward to posting additional data from the trial program with the regulatory authorities and scientific community as they prepare to advance with international regulatory submissions.

Risankizumab is part of an association with Boehringer Ingelheim, with AbbVie directing future commercialization and development of risankizumab internationally. Top-line data of the three other risankizumab Phase III psoriasis pivotal trials were previously reported in October 2017.

In the last trading session, the stock price of AbbVie declined more than 1% to close the day at $95.22.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement